广西医科大学学报2017，Vol.34Issue(7)：1019-1023,5.DOI:10.16190/j.cnki.45-1211/r.2017.07.018
贝伐珠单抗联合盐酸厄洛替尼治疗晚期非小细胞肺癌EGFR不同外显子突变的疗效分析
Clinical effect of bevacizumab combined withEGFR-TKI therapy on non-small cell lung cancer patients with different EGFR mutations
翁克贵 1蒋勇 1王颖1
作者信息
- 1. 重庆市肿瘤研究所/重庆市肿瘤医院/重庆市癌症中心,重庆400030
- 折叠
摘要
Abstract
Objective:To investigate the clinical efficacy of bevacizumab combined with tyrosine kinase inhibitor (TKI) targeted therapy on the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 19 or 21 mutation.Methods:96 advanced NSCLC patients with EGFR mutation treated in our hospital from June 2014 to July 2015 were enrolled.Of them,48 cases had EGFR exon 19 mutation and 48 cases had EGFR exon 21 mutation.They were both divided into a study group and a control group,with 24 cases in each group.The patients in the control group received erlotinib hydrochloride tablets only,while those in the study group were treated as the control group with addition of bevacizumab.The total effective rate,1-year survival rate,median time to progression (TPP) and the quality of life (QOL) scale scores were compared between the control group and the study group.Results:The total effective rate,TPP,1-year survival rate and QOL scores of patients with EGFR exon 19 or 21 mutation in the study group were significantly higher than those in the control group (P＜0.05 or P ＜0.01).There was no significant difference in the incidence of adverse reactions between the control group and the study group (P＞0.05).Conclusion:Bevacizumab combined with TKI targeted therapy was effective in the treatment of advanced NSCLC.This combination could increase patients' survival rate,improve prognosis and prolong TTP,and was safety.关键词
贝伐珠单抗/靶向治疗/非小细胞肺癌/临床疗效Key words
bevacizumab/targeted therapy/non-small cell lung cancer/clinical efficacy分类
医药卫生引用本文复制引用
翁克贵,蒋勇,王颖..贝伐珠单抗联合盐酸厄洛替尼治疗晚期非小细胞肺癌EGFR不同外显子突变的疗效分析[J].广西医科大学学报,2017,34(7):1019-1023,5.
